Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in ChildrenThe SCOUT-CAP Randomized Clinical Trial

Childhood community-acquired pneumonia (CAP) is usually treated with 10 days of antibiotics. Shorter courses may be effective with fewer adverse effects and decreased potential for antibiotic resistance. Objective To compare a short (5-day) vs standard (10-day) antibiotic treatment strategy for CAP in young children. Design, Setting, and Participants Randomized double-blind placebo-controlled clinical trial in outpatient …

Continue reading Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in ChildrenThe SCOUT-CAP Randomized Clinical Trial

Neutrophil-to-Lymphocyte Ratio Better Than High-Sensitivity C-Reactive Protein in Predicting Stroke-Associated Pneumonia in Afebrile Patients

To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and stroke-associated pneumonia (SAP) in patients with acute ischemic stroke (AIS) without fever and to clarify whether NLR has an advantage over high-sensitivity C-reactive protein (hs-CRP) in predicting SAP. Patients and Methods: A total of 434 patients with AIS without fever were assessed in this study. Multivariable …

Continue reading Neutrophil-to-Lymphocyte Ratio Better Than High-Sensitivity C-Reactive Protein in Predicting Stroke-Associated Pneumonia in Afebrile Patients

Empiric #antibiotics for community-acquired #pneumonia in adult patients: a systematic review and a network meta-analysis

The main aim of this network meta-analysis is to identify the empiric antibiotic (Em-ATB) with the highest probability of being the best (HPBB) in terms of (1) cure rate and (2) mortality rate in hospitalised patients with community acquired pneumonia (CAP) . Method Inclusion criteria: (1) adult patients (>16 years old) diagnosed with CAP that required …

Continue reading Empiric #antibiotics for community-acquired #pneumonia in adult patients: a systematic review and a network meta-analysis

Short-Course #Antimicrobial Therapy for Pediatric Community-Acquired #Pneumonia The SAFER Randomized Clinical Trial

Community-acquired pneumonia (CAP) is a common occurrence in childhood; consequently, evidence-based recommendations for its treatment are required. Objective To determine whether 5 days of high-dose amoxicillin for CAP was associated with noninferior rates of clinical cure compared with 10 days of high-dose amoxicillin. Design, Setting, and Participants The SAFER (Short-Course Antimicrobial Therapy for Pediatric Respiratory …

Continue reading Short-Course #Antimicrobial Therapy for Pediatric Community-Acquired #Pneumonia The SAFER Randomized Clinical Trial

JAK inhibition reduces #SARS-CoV-2 #liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

Using AI we identified baricitinib as possessing anti-viral and anti-cytokine efficacy. We now show a 71% (95% CI 0.15-0.58) mortality benefit in 83 patients with moderate-severe SARS-CoV-2 pneumonia with few drug-induced adverse events, including a large elderly cohort (median age 81 years). A further 48 cases with mild-moderate pneumonia recovered uneventfully. Using organotypic 3D cultures …

Continue reading JAK inhibition reduces #SARS-CoV-2 #liver infectivity and modulates inflammatory responses to reduce morbidity and mortality